摘要
目的:评价健脾中药胃肠安对晚期胃癌生存期的影响。方法:采用双向性同期对照临床研究,在基线均衡的条件下比较接受健脾中药联合化疗的治疗组和仅接受化疗的同期对照组的生存期。Cox多因素回归模型分析影响晚期胃癌独立预后因素,Kaplan-Meier法估算中位生存时间(OS)。结果:共有935例晚期胃癌病例纳入研究,包括597例对照组和338例治疗组。Cox多因素分析显示,性别(P=0.010),靶向治疗(P=0.037),姑息性手术(P=0.000),健脾中药(P=0.000)是影响晚期胃癌患者生存期的独立预后因素。以是否行姑息性手术分层:姑息性手术亚组中,治疗组(188例)的中位OS 21.8个月较对照组(249例)的15.6个月延长(P=0.004)。非姑息性手术亚组中,治疗组(150例)的中位OS 16.3个月较对照组(348例)的12.6个月延长(P=0.002)。结论:健脾中药胃肠安是影响晚期胃癌预后的独立保护性因素,联合化疗可使晚期胃癌患者生存获益。
Objective:To evaluate the herbal formula for invigorating spleen combined with chemotherapy in advanced gastric cancer based on Weichangan.Methods:Compared the lifetime of the treatment group receiving spleen Chinese medicine combined with chemotherapy and the control group receiving only chemotherapy under the baseline equilibrium conditions by bidirectional concurrent controlled clinical study.Cox multivariate regression model was used to analyze the independent prognostic factors of advanced gastric cancer.Kaplan-Meier method was used to estimate the median survival time(OS).Results:A total of 935 cases of advanced gastric cancer were included in the study,including 597 control groups and 338 treatment groups.Cox regression analysis suggested that sex(P=0.010),molecular targeted therapy(P=0.037),previous(P=0.000),invigorating spleen Chinese herbs(P=0.000)were independent prognostic factors affecting lifetime of patients with advanced gastric cancer.In the subgroup of palliative surgery,the median OS of the treatment group(188 cases)was 21.8 months longer than that of the control group(249 cases)for 15.6 months(P=0.004).In the subgroup of non-palliative surgery,the median OS of the treatment group(150 cases)was 16.3 months longer than that of the control group(348 cases)for 12.6 months(P=0.002).Conclusion:The herbal formula for invigorating spleen was dependent protective factor affecting the prognosis of advanced gastric cancer based on Weichangan,combined chemotherapy can benefit the lifetime of patients with advanced gastric cancer.
作者
李朝燕
赵爱光
竹永宝
徐燕
朱晓虹
曹妮达
刘天舒
赵刚
郭伟剑
丁红华
刘丽坤
LI Zhao-yan;ZHAO Ai-guang;ZHU Yong-bao;XU Yan;ZHU Xiao-hong;CAO Ni-da;LIU Tian-shu;ZHAO Gang;GUO Wei-jian;DING Hong-hua;LIU Li-kun(First Department of Oncology,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Department of Medical Oncology,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200032,China;Department of Surgery,Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200120,China;Department of Medical Oncology,Cancer Hospital of Fudan University,Shanghai 200032,China;Department of Oncology,First People’s Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200080,China;Department of Oncology,Shanxi Provincial Hospital of Traditional Chinese Medicine,Taiyuan 030012,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2019年第5期2012-2017,共6页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家重点研发计划(No.2017YFC1700605)
国家科技重大专项(No.2017ZX09304-001)
国家中医临床研究基地业务建设科研专项(No.JDZX2015068)~~
关键词
晚期胃癌
健脾
化疗
生存期
预后
Advanced gastric cancer
Invigorating spleen
Chemotherapy
Lifetime
Prognosis